NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
NovoCure Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$14.89+0.82 (+5.83%)
Close on Oct 19, 2026
- Market cap
- $1.73B
- P/E (TTM)
- –
- Dividend yield
- –
NovoCure Ltd revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $102.96M | $95.96M | $101.61M | $96.61M | $94.26M | $93.15M | $107.20M | $98.35M | $95.71M | $90.54M | $91.31M | $86.24M | 56.1% | +9.2% |
| International markets - Total | $74.67M | $73.30M | $68.11M | $65.00M | $59.95M | $57.22M | $52.09M | $52.13M | $48.80M | $43.02M | $38.07M | $34.32M | 40.7% | +24.6% |
| Germany | $23.34M | $24.50M | $21.33M | $20.29M | $19.07M | $18.72M | $17.43M | $16.99M | $15.10M | $15.75M | $14.66M | $14.68M | 12.7% | +22.4% |
| France | $21.35M | $22.88M | $20.29M | $19.62M | $18.42M | $17.86M | $15.73M | $15.24M | $14.27M | $10.49M | $7.58M | $4.16M | 11.6% | +15.9% |
| Other international markets | $18.21M | $15.68M | $16.28M | $15.71M | $12.98M | $11.94M | $10.42M | $11.31M | $11.77M | $8.97M | $8.28M | $7.89M | 9.9% | +40.3% |
| Japan | $11.78M | $10.24M | $10.21M | $9.39M | $9.48M | $8.71M | $8.51M | $8.58M | $7.66M | $7.82M | $7.55M | $7.59M | 6.4% | +24.2% |
| China | $5.96M | $4.80M | $4.64M | $5.60M | $4.59M | $4.62M | $1.98M | $4.63M | $5.85M | $4.94M | $4.40M | $6.76M | 3.2% | +29.7% |
| Others | – | – | – | – | – | – | – | – | – | – | – | $12.05M | – | – |
From the segment and revenue-disaggregation notes of NovoCure's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.